Clinical Trial Update: A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating talazoparib, radiotherapy, and atezolizumab in gBRCA1/2-negative, PD-L1 positive metastatic triple-negative breast cancer; study termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Radiotherapy
• Talazoparib (talazoparib)

Snippet

Sponsor: Mylin A. Torres, MD | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-12-04